Letter to shareholders re: Dr Anne Brindley – (Reach – non-regulatory announcement)

22nd July 2021

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the RNS issued yesterday on the departure of Dr Anne Brindley as CEO, the Company has issued a letter to shareholders. The letter can be viewed here: https://nuformix.com/document-center/

Download News

Back to all News